Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Abstract Text:

Noboru Yamamoto,Atsushi Horiike,Yasuhito Fujisaka,Haruyasu Murakami,Tatsu Shimoyama,Yasuhide Yamada,Tomohide Tamura,Noboru Yamamoto,Atsushi Horiike,Yasuhito Fujisaka,Haruyasu Murakami,Tatsu Shimoyama,Yasuhide Yamada,Tomohide Tamura,

PURPOSE: The objectives of this phase I dose-finding study of erlotinib were to investigate the toxicity profile, to confirm the acceptable toxicity of doses up to 150 mg/day, and to assess the pharmacokinetic (PK) profile and antitumor activity in Japanese patients with solid tumors. PATIENTS AND METHODS: Patients with solid tumors not amenable to standard forms of treatment were included. Treatment cycle 1 consisted of single-dose administration on day 1, withdrawal on day 2, continuous daily administration from days 3-23, and withdrawal from days 24-30. Subsequent cycles (28 days) used continuous daily administration. The dose of erlotinib was escalated from 50 mg/day to 150 mg/day in 50-mg increments. PK evaluation was performed in all patients during cycle 1. RESULTS: Fifteen patients, aged 38-70 (median; 57) years with non-small-cell lung (n = 11), colorectal (n = 3) or head and neck (n = 1) cancer were enrolled. The major toxicities were rash, diarrhea and liver dysfunctions, which were generally mild and easily manageable. The good tolerability of erlotinib up to the dose of 150 mg/day was confirmed. One patient developed grade 5 treatment-related interstitial pneumonitis. Four of 11 evaluable patients achieved partial responses; all four had non-small-cell lung cancer (NSCLC). The peak plasma concentration of erlotinib, and the area under the concentration-time curve increased proportionally to the dose, suggesting linear PK. CONCLUSION: The recommended dose of erlotinib in Japanese patients is 150 mg/day. Further trials in Japanese NSCLC patients are warranted.

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Publishing Authors By Initials

N Yamamoto,A Horiike,Y Fujisaka,H Murakami,T Shimoyama,Y Yamada,T Tamura,N Yamamoto,A Horiike,Y Fujisaka,H Murakami,T Shimoyama,Y Yamada,T Tamura,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy and pharmacology

VOLUME: 61

Page Numbers: 489-96

Journal Abbreviation: Cancer Chemother. Pharmacol.

ISSN: 0344-5704

DAY: 5

MONTH: 05

YEAR: 2007

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7806519

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.

AFFILIATION: Division of Internal Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji Chuo-ku, Tokyo, 104-0045, Japan, ttamura@ncc.go.jp.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 erlotinib in Japanese patients with solid tumors Related Publications

• 13C-enrichment at carbons 8 and 2 of uric acid after 13C-labeled folate dose in man.
• Antibacterial polypeptide produced by Streptomyces carzinostaticus. I. Isolation and purification of active substances.
• Concurrent chemoradiotherapy for limited-disease small cell lung cancer in elderly patients aged 75 years or older.
• Disruption of the mouse protein Ser/Thr phosphatase 2Cbeta gene leads to early pre-implantation lethality.
• Easily installable behavioral monitoring system with electric field sensor.
• Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
• Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
• Establishment of cell lines that exhibit pluripotency from miniature swine periodontal ligaments.
• Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review.
• Increasing trend of spina bifida and decreasing birth weight in relation to declining body-mass index of young women in Japan.
• Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation.
• Inhalation and incubation with procaterol increases diaphragm muscle contractility in mice.
• Involvement of insulin-like growth factor-binding protein-related protein 1 in decidualization of human endometrial stromal cells.
• Measurement of blood vessel diameter for angiography using refraction contrast imaging.
• Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
• Phase I study of cisplatin analogue nedaplatin, paclitaxel, and thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
• Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients.
• Random evolution and coherence degradation of a high-order optical soliton train in the presence of noise.
• Recovery of respiratory motion and deformation of the liver using laparoscopic freehand 3D ultrasound system.
• Serum total bilirubin as a predictive factor for severe neutropenia in lung cancer patients treated with cisplatin and irinotecan.
• Single-longitudinal-mode scan of a pulsed double-grating Ti:sapphire oscillator.
• Specification of cell fate along the proximal-distal axis in the developing chick limb bud.
• Studies on nitrite reductase from spinach leaves. I. Further purification and some properties.
• The effect of calcium ion on the biodegradation of octylphenol polyethoxylates, and the antiandrogenic activity of their biodegradates.
• Thoracoscopic surgical navigation system for cancer localization in collapsed lung based on estimation of lung deformation.
• Wearable accelerometer in clinical use.
• [Chronic constrictive pericarditis]
• [Determination of dl-alpha-tocopherol acetate and dl-alpha-tocopherol in foods by HPLC using post-column photochemical reaction]
• [Late appearance of chronic constrictive pericarditis]
• [Pericarditis in collagen vascular disease]